Key result
Short-term Lp(a) variability drives threshold reclassification in clinical trial placebo arms.
Key points are not available for this paper at this time.
Answers are grounded in this paper and cite their sources.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Szarek et al. (2026) studied this question. Lipoprotein(a) exhibits short-term variability that leads to threshold reclassification in the placebo arms of Phase 3 obicetrapib trials.
Synapse has enriched 10 related papers. Consider them for comparative context: